Related Experiment Video
Updated: Jul 20, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Emerging drugs for Parkinson's disease
1Medical College of Georgia, Movement Disorders Program, Department of Neurology, 1429 Harper Street, HF-1121, Augusta, GA 30912, USA. jmorgan@mcg.edu
Expert Opinion on Emerging Drugs
|August 31, 2006
Summary
Levodopa is effective for Parkinson's disease (PD) motor symptoms, but new drugs are needed for non-levodopa-responsive and nonmotor symptoms, as well as disease-slowing therapies.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) affects millions globally, with levodopa as the primary treatment.
- Levodopa effectively manages early motor symptoms but struggles with later-stage motor and nonmotor symptoms.
Purpose of the Study:
- To review emerging pharmacotherapies for Parkinson's disease.
- To discuss novel agents targeting both motor and nonmotor symptoms.
- To explore potential disease-slowing and neuroprotective treatments for PD.
Main Methods:
- Literature review of current and emerging Parkinson's disease treatments.
- Analysis of drug development pipelines for PD symptom management.
- Examination of research on neuroprotective strategies in PD.
Main Results:
- Emerging drugs show promise for non-levodopa-responsive motor symptoms like postural instability.
- Significant focus is placed on developing treatments for nonmotor symptoms, including depression and dementia.
- Research is actively pursuing disease-modifying therapies to slow PD progression.
Conclusions:
- New pharmacological approaches are crucial for comprehensive Parkinson's disease management.
- Future treatments aim to address a broader spectrum of PD symptoms and slow disease advancement.
- Continued research into novel agents and neuroprotection is vital for improving patient outcomes.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...